ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,750Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 224

$476K Total Retail Price of All Prescriptions

Rank: 15 out of 224

375 Patients Receiving at Least One Drug in Part D
63%Patients 65 Years and Older
74% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 375 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

12% of this provider’s 375 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 4,791 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
SIMVASTATIN 353 237 1 1
OMEPRAZOLE 339 174 2 3
LISINOPRIL 266 186 3 2
HYDROCODONE-ACETAMINOPHEN 224 47 S3 4 12
LEVOTHYROXINE SODIUM 213 142 5 4
HYDROCHLOROTHIAZIDE 180 129 6 6
FUROSEMIDE 177 142 7 5
METOPROLOL TARTRATE 157 121 8 7
OXYCODONE HCL 143 25 S2 9 25
ATENOLOL 142 76 10 13
TRAMADOL HCL 135 67 11 18
SERTRALINE HCL 126 69 12 17
GABAPENTIN 117 66 13 14
METFORMIN HCL 116 86 14 9
FAMOTIDINE 113 64 15 77
METHADONE HCL 109 0 S2 16 53
ZOLPIDEM TARTRATE 106 41 17 22
TRAZODONE HCL 101 69 18 20
LYRICA 93 41 19 85
IBUPROFEN 91 21 20 51
PROAIR HFA 84 55 21 26
CITALOPRAM HBR 83 44 22 15
MIRTAZAPINE 82 75 23 54
LOSARTAN POTASSIUM 79 65 24 19
RISPERIDONE 77 58 25 50
PAROXETINE HCL 77 53 25 52
OXYCODONE HCL-ACETAMINOPHEN 73 0 S2 27 142
DONEPEZIL HCL 73 72 27 36
WARFARIN SODIUM 73 58 27 10
ATORVASTATIN CALCIUM 72 56 30 16
TAMSULOSIN HCL 71 65 31 30
LANTUS 70 30 32 43
METOPROLOL SUCCINATE 69 49 33 11
PANTOPRAZOLE SODIUM 68 40 34 27
VENLAFAXINE HCL ER 66 0 35 66
BUSPIRONE HCL 59 21 36 161
CYCLOBENZAPRINE HCL 58 0 R 37 76
OXYCODONE-ACETAMINOPHEN 58 22 S2 37 41
PREDNISONE 56 34 39 28
AMLODIPINE BESYLATE 56 42 39 8
BUPRENORPHINE HCL 53 0 S3 41 167
AZITHROMYCIN 53 30 41 46
SUBOXONE 53 0 41 31
CEPHALEXIN 52 47 44 97
LANTUS SOLOSTAR 50 29 45 60
TRIAMCINOLONE ACETONIDE 50 32 45 93
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.